![Sample our Engineering & Technology journals, sign in here to start your access, latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5933/TOC-Subject-Sample-2021-Engineering-Tech.jpg"})
Abstract
Insulin pens offer significant benefits over vial and syringe injections for patients with diabetes who require insulin therapy. Insulin pens are more discreet, easier for patients to hold and inject, and provide better dosing accuracy than vial and syringe injections. The Humalog® KwikPen™ (prefilled insulin lispro [Humalog] pen, Eli Lilly and Company, Indianapolis, IN, USA) is a prefilled insulin pen highly rated by patients for ease of use in injections, and has been preferred by patients to both a comparable insulin pen and to vial and syringe injections in comparator studies. Together with an engineering study demonstrating smoother injections and reduced dosing error versus a comparator pen, recent evidence demonstrates the Humalog KwikPen device is an accurate, easy-to-use, patient-preferred insulin pen.
Acknowledgements
The authors gratefully acknowledge Joseph Durrant (i3 Statprobe), Caron Modeas (i3 Statprobe), Margaret Campbell (Eli Lilly and Company), Tina Rees (Eli Lilly and Company) and Mayme Wong (Eli Lilly and Company) for critical review and assistance with manuscript preparation.
Financial & competing interests disclosure
The contents of this manuscript, including conclusions and expert commentary, represent the independent work of the authors. All authors participated in the development and review of the paper and approved the submitted version. All clinical trials of products of Eli Lilly and Company discussed herein were funded by Eli Lilly and Company.
Debra A Ignaut is an employee and stockholder of Eli Lilly and Company. Jennifer N Bodie is a scientific writer employed full-time by i3 Statprobe, a division of Ingenix which is a subsidiary of UnitedHealth Group. Eli Lilly and Company contracted with i3 Statprobe for the technical writing and editing of this manuscript. Sherwyn L Schwartz is the Chief Executive Officer and Chief Medical Officer of Diabetes & Glandular Disease Research, Inc., and has served as a medical advisor to Eli Lilly and Company. The authors have no other relevant affiliations or financial involvement with any organization or entity with financial interest in or financial conflict with the subject matter or data discussed in the manuscript, apart from those disclosed.
No other writing assistance was utilized in the production of this manuscript.